文摘
摘要目的:没有代理生物标志物的帕金森病(PD)已确定。另一方面,一个非侵入性的生物标志物是至关重要的理解自然历史,严重性,帕金森病的进展和指导未来的治疗试验。这个探索性研究评估细胞外囊泡的作用(EVs)和聚ADP-ribose聚合酶(PAR)等离子体帕金森病病人的非侵入性疾病严重程度和进展的标志。
背景:NA
设计/方法:我们收集57帕金森病病人的血浆(复制队列发现队列20日37)20个人影响,并与20例临床诊断阿尔茨海默氏症,与路易体痴呆。我们分析alpha-synuclein-positive EVs从platelet-free等离子体纳米流式细胞术和血药浓度的票面使用夹心ELISA试剂盒。
结果:中等浓度的α-synuclein EVs明显高于PD患者相比其他组(克鲁斯卡尔-沃利斯,p <。)。患者在发现人群中,高α-synuclein细胞外囊泡有较高统一帕金森病评定量表评分(UPDRS III中值= 22日与5,p = 0.045)。七的20例(35%)显示检测到标准水平的水平明显高于阳性患者显示α-synuclein电动汽车。在确认中,我们没有观察到显著的差异与UPDRS PAR阳性病例的关系。
结论:非侵入性测定α-synuclein-positive电动汽车可能会提供一个潜在的非侵入性标记的PD疾病严重程度和纵向研究需要评估的角色α-synuclein-positive EVs疾病进展的标志。
披露:吕西安博士没有披露。Benarroch博士没有披露。艾丹马伦没有披露。阿里博士没有披露。Boeve博士已经收到个人薪酬在10000 - 49999美元的范围作为一个军官或雨水慈善基金会的董事会成员。Boeve博士的机构收到生原体的研究支持。Boeve博士的机构收到EIP制药的研究支持。Boeve博士的机构已经接到Alector研究支持。Boeve博士的机构已收到研究通用电气医疗集团的支持。Boeve博士已经收到相关出版物的出版版税卫生保健。 Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Brain Protection Company. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck, Inc.. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc.. Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche, Inc.. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Mr. Stang has nothing to disclose. Dr. Camerucci has nothing to disclose. Dr. Ross has nothing to disclose. Dr. Wszolek has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Polish Neurological Society/Via Medica. Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Bower has received research support from Abbvie. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Icon PLC. The institution of Dr. Singer has received research support from NIH. Dr. Singer has received intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.
